Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Stephen Padilla, 31 Jan 2020
The combination of ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (DMR) delivers faster responses, better response rates and greater satisfaction compared with monotherapy in patients with severe rosacea, a recent study has shown.
26 Jun 2020
Dapagliflozin 5 mg and 10 mg FC tab
26 Jun 2020
Apalutamide 60 mg film-coated tab

Fezolinetant eases vasomotor symptoms, improves quality of life

26 Aug 2020

Treatment with oral fezolinetant leads to a reduction in vasomotor symptoms (VMS) with large parallel improvements in quality of life, according to data from the phase IIb VESTA trial.

In the 12-week trial, 352 postmenopausal women with VMS were randomly assigned to the following treatment groups: fezolinetant 15 mg (n=45), 30 mg (n=43), 60 mg (n=45), and 90 mg (n=45) twice daily (BID); or 30 mg (n=43), 60 mg (n=45), and 120 mg (n=44) once daily (QD); or placebo (n=43). At baseline, the women were aged 40–65 years and had body mass index of 18–38 kg/m2. They reported having 50 moderate-to-severe VMS per week.

Compared with placebo, all fezolinetant doses were associated with marked reductions in VMS frequency at weeks 4 (mean, −1.9 to −3.5) and 12 (mean, −1.8 to −2.6; p<0.05). Likewise, severity decreased by a mean of 0.4 to 1.0 with all doses (p<0.05) at week 4 and by 0.2 to 0.6 with the 60-mg and 90-mg BID and 60-mg QD (p<0.05) at week 12.

VMS frequency reductions were accompanied by clinically meaningful changes in patient-reported outcomes. For instance, all doses of fezolinetant improved scores on the Hot Flash-Related Daily Interference Scale at weeks 4 (placebo: −2.2; fezolinetant: range, −2.5 to −3.8) and 12 (placebo: −2.9; fezolinetant: range, −3.3 to −4.3), as well as on the Menopause-Specific Quality of Life questionnaire (week 4, placebo: −1.8; fezolinetant: range, −1.9 to −3.6; week 12, placebo: −2.3; fezolinetant: range, −2.9 to −4.4).

Also, Greene Climacteric Scale-VMS domain scores improved for most fezolinetant doses at both time points (week 4, placebo: −1.7; fezolinetant: range, −2.1 to −3.3; week 12, placebo: −2.1; fezolinetant: range, −2.7 to −3.6).

Treatment-emergent adverse events were mostly mild or moderate, occurring similarly across all fezolinetant groups.

The findings suggest that the neurokinin 3 receptor antagonist fezolinetant, a nonhormonal therapy, may be an attractive treatment option in women with moderate-to-severe VMS associated with menopause, which could translate into meaningful improvements in quality of life, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Stephen Padilla, 31 Jan 2020
The combination of ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (DMR) delivers faster responses, better response rates and greater satisfaction compared with monotherapy in patients with severe rosacea, a recent study has shown.
26 Jun 2020
Dapagliflozin 5 mg and 10 mg FC tab
26 Jun 2020
Apalutamide 60 mg film-coated tab